American Association for Clinical Chemistry
Better health through laboratory medicine
Tumor Markers Quality Requirements

The National Academy of Clinical Biochemistry
Laboratory Medicine Practice Guidelines
Use of Tumor Markers in Clinical Practice: Quality Requirements

Published Guidelines
Access to Table of Contents

These guidelines are intended to encourage more appropriate use of tumor marker tests by primary care physicians, hospital physicians and surgeons, specialist oncologists, and other health care professionals. The background and methodology described within this document represent the larger undertaking to address tumor markers in clinical practice of which this set of guidelines is a part. The recommendations contained herein are based upon the best available evidence and consensus of expert contributors and reviewers. Toward this effort, draft revisions of these guidelines were prepared and placed for comment on the NACB web site. The guideline chapters resulting from this process have been published in appropriate peer-reviewed laboratory medicine and specialty clinical journals to assist with dissemination among the target groups.

Committee (Author) Disclosures

NACB Committee Members:

Catherine Sturgeon, PhD
Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Eleftherios P. Diamandis, PhD
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Barry R. Hoffman, PhD
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Daniel W. Chan, PhD
Department of Pathology, Center for Biomarker Discovery, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Soo-Ling Ch’ng, PhD, MD
Tanjung Bungah, Penang, Malaysia

Elizabeth Hammond, PhD
Department of Pathology, LDS Hospital, Salt Lake City, UT, USA

Daniel F. Hayes, MD
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

Lance A. Liotta, PhD
Center for Applied Proteomics and Molecular Medicine, College of Sciences, George Mason University, Manassas, VA, USA

Emmanuel F. Petricoin, PhD
Center for Applied Proteomics and Molecular Medicine, College of Sciences, George Mason University, Manassas, VA, USA

Manfred Schmitt, PhD
Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany

O. John Semmes, PhD
Department of Microbiology and Molecular Cell Biology, Center for Biomedical Proteomics, Eastern Virginia Medical School, Norfolk, VA, USA

Györg Söletormos, PhD
Department of Clinical Biochemistry, Hillerød Hospital, Hillerød Denmark

Elena van der Merwe, PhD
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

This LMPG was developed by an independent committee of the NACB. Subsequent publication of these guidelines has been supported by the Academy.